BacoCure
Bacterial Products for Treatment of Non-muscle Invasive Bladder Cancer
Company Overview
Snapshot
Founded in February 2018 by Ofer Mandelboim, Yutkin Vladimir, and Gili (Gilad) Bachrach, BacoCure operates with 1-10 employees. The company has secured funding across one disclosed round from one investor. In February 2018, BacoCure received seed funding from Integra Holdings.
Business overview
BacoCure is a Health Tech & Life Sciences company focused on developing novel bacterial products for the local treatment of non-muscle invasive bladder cancer. Its core product is a mutated and inactivated uropathogenic bacteria designed to provide anti-tumor effects through a differentiated mechanism of action with an improved safety profile compared to existing treatments like Bacillus Calmette-Guerin. The company operates in the Pharmaceuticals & Diagnostics sector, serving the healthcare and life sciences markets, specifically targeting patients with bladder cancer.
Log in to access full profile ›Company Intelligence Q&A
- What is BacoCure's primary focus?
- BacoCure is developing a novel bacterial product for the local therapy of patients with non-muscle invasive bladder cancer, aiming to provide an improved safety profile compared to existing treatments.
- When was BacoCure founded and by whom?
- BacoCure was founded in February 2018 by Ofer Mandelboim, Yutkin Vladimir, and Gili (Gilad) Bachrach.
- What is the current development stage of BacoCure's lead product?
- BacoCure's lead product is currently at an advanced preclinical development stage.
- What is BacoCure's status as of January 2022?
- BacoCure ceased to operate in January 2022 and is currently listed as Non-Active.
- What is BacoCure's core product?
- BacoCure's core product is a novel mutated and inactivated uropathogenic bacteria designed to provide anti-tumor effects with an improved safety profile.